

Vertex – “Testing Time Ahead for INCIVEK - After 2013!”

<https://marketpublishers.com/r/V806911DE58EN.html>

Date: November 2011

Pages: 10

Price: US\$ 140.00 (Single User License)

ID: V806911DE58EN

Abstracts

INCIVEK (Telaprevir, L, HCV) should sustain its momentum till FY13 and only successful launch of Gilead/VRUS's and others IFN-free drugs in 2014, would result in declining sales for INCIVEK/IFN combination. Vertex (VRTX) next target is to capture the HCV/HIV co-infected patients and gain greater HCV market through shorter duration and dosing advantage to a niche pts population of IL28B CC Genotype. Down side risk are hedged due to pipeline drugs targeting Rheumatoid Arthritis (RA), Cystic Fibrosis (CF), etc. For more details, please read our report released on 25th November, 2011 on VRTX titled “Testing Time Ahead for INCIVEK - After 2013!”

Contents

COMPANIES MENTIONED

Vertex

I would like to order

Product name: Vertex – “Testing Time Ahead for INCIVEK - After 2013!”

Product link: <https://marketpublishers.com/r/V806911DE58EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V806911DE58EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970